Aprogen Pharmaceuticals Inc (KO:003060) — Market Cap & Net Worth
Market Cap & Net Worth: Aprogen Pharmaceuticals Inc (003060)
Aprogen Pharmaceuticals Inc (KO:003060) has a market capitalization of $503.85 Million (₩743.49 Billion) as of May 4, 2026. Listed on the KO stock exchange, this Korea-based company holds position #12493 globally and #399 in its home market, demonstrating a 1369.97% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aprogen Pharmaceuticals Inc's stock price ₩3763.12 by its total outstanding shares 197572806 (197.57 Million). Analyse 003060 cash flow conversion to see how efficiently the company converts income to cash.
Aprogen Pharmaceuticals Inc Market Cap History: 2015 to 2026
Aprogen Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $2.18 Billion to $503.85 Million (-14.93% CAGR).
Aprogen Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aprogen Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Aprogen Pharmaceuticals Inc's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.18 Billion | $40.32 Billion | $2.76 Billion | 0.05x | 0.79x |
| 2016 | $2.67 Billion | $44.12 Billion | -$3.92 Billion | 0.06x | N/A |
| 2017 | $2.79 Billion | $46.10 Billion | -$16.36 Billion | 0.06x | N/A |
| 2018 | $1.62 Billion | $45.40 Billion | -$1.22 Billion | 0.04x | N/A |
| 2019 | $1.21 Billion | $50.90 Billion | -$8.31 Billion | 0.02x | N/A |
| 2020 | $1.34 Billion | $53.32 Billion | $11.25 Billion | 0.03x | 0.12x |
| 2021 | $920.84 Million | $56.48 Billion | $8.10 Billion | 0.02x | 0.11x |
| 2022 | $511.80 Million | $65.19 Billion | $12.64 Billion | 0.01x | 0.04x |
| 2023 | $295.08 Million | $87.36 Billion | -$118.27 Billion | 0.00x | N/A |
| 2024 | $88.64 Million | $67.38 Billion | -$104.98 Billion | 0.00x | N/A |
Competitor Companies of 003060 by Market Capitalization
Companies near Aprogen Pharmaceuticals Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Aprogen Pharmaceuticals Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.15 |
Aprogen Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Aprogen Pharmaceuticals Inc's market cap moved from $2.18 Billion to $ 503.85 Million, with a yearly change of -14.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩503.85 Million | +625.07% |
| 2025 | ₩69.49 Million | -21.60% |
| 2024 | ₩88.64 Million | -69.96% |
| 2023 | ₩295.08 Million | -42.35% |
| 2022 | ₩511.80 Million | -44.42% |
| 2021 | ₩920.84 Million | -31.18% |
| 2020 | ₩1.34 Billion | +10.17% |
| 2019 | ₩1.21 Billion | -25.24% |
| 2018 | ₩1.62 Billion | -41.83% |
| 2017 | ₩2.79 Billion | +4.73% |
| 2016 | ₩2.67 Billion | +22.15% |
| 2015 | ₩2.18 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Aprogen Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $503.85 Million USD |
| MoneyControl | $503.85 Million USD |
| MarketWatch | $503.85 Million USD |
| marketcap.company | $503.85 Million USD |
| Reuters | $503.85 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aprogen Pharmaceuticals Inc
Aprogen Biologics Inc. manufactures and sells pharmaceutical products primarily in South Korea. The company was founded in 1960 and is headquartered in Seoul, South Korea.